Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KULR Technology Group, Inc. stock price fell by -3.28% on the last day (Tuesday, 28th Dec 2021) from $3.05 to $2.95. During the day the stock fluctuated 7.00% from a day low at $2.91 to a day high of $3.11. The price has been going up and down for this period, and there has been a 0.68% gain for the last 2 weeks. Volume has increased on the last day by 242 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 969 thousand shares were bought and sold for approximately $2.86 million.
Given the current short-term trend, the stock is expected to rise 38.85% during the next 3 months and, with a 90% probability hold a price between $4.10 and $5.99 at the end of this 3-month period
Day traders do what they do, lose money selling on drops of a company growing at 300% + per year. No vision with those traders, just buy , sell and move on. It could be growing at 5000% per year and they would sell on a $.05 rise in price.
Many have avg up just like you.
Wow, great posting and well done on the timeline (nothing happening). The blind can not see , even when it is in front of them. Thanks for the reposting .
Several cancer therapies seem to cure psoriasis, but the therapy is never used for that ailment. It is just a side affect noted from clinical and therapy when the patient happens to have psoriasis.
More fraudulent shares sold at opening by short criminals who care not about being exposed by SEC and DOJ. I say this because no one in their right mind would sell actual shares at this juncture .
Why are shorts panicking and using all the fraudulent shares and arguments they can dare to invent?
Maybe a few who have engaged in racketeering over the years will finally get thrown in prison for the rest of their lives and be fined $ billions or all assets. They could start with some posting here, twitter, telegram, Yahoo and other short sites .
There are no constraints restricting anyone from selling and buying that 100% winner they see as an alternative to a developing biotech with a new SOC for glioblastoma patients. Those who are not happy, constitute a few million share maybe. Those content , hold almost a billion shares.
The rest of the world isn’t bought off like the FDA. Look for the UK to approve and embarrass the FDA . Israel or Japan will probably approve before FDA. Merck has a lot of clinical work going on in Japan.
God bless all
The thought of what isn’t said, makes me content to know I am owning a portfolio changer X 40 at the very least.
God bless and stay safe.
Some for sale may actually be real shares backed by more than a crooked fraud.
Hindsight is always 20/20
https://insideri.com/1662684_000110465921152800_0001104659-21-152800
Timothy Knowes Chief Technical Officer’s wife sold stock
Explanation of Responses:
1. The Reporting Person's acquisition of, and indirect ownership of, the 1,000,000 shares of common stock of KULR Technology Group, Inc. (the "Company") is the result of his marriage to his spouse, Marianne Knight on February 14, 2019. Mr. Knowles does not have direct voting or dispositive control over the shares owned by Ms. Knight. The Amount of securities beneficially owned following the reported transactions do not include Mr. Knowles' direct ownership over 15,600,000 shares, which amount remains unchanged since Mr. Knowles' initial acquisition of the Company's common stock.
2. On December 20, 2021, Marianne Knight, Mr. Knowles' spouse, sold 92,266 shares of common stock of the Company at a price of $2.849941 per share.
3. On December 21, 2021, Marianne Knight, Mr. Knowles' spouse, sold 37,734 shares of common stock of the Company at a price of $2.911547 per share
Complications that vary even state to state.
The short history of biotech and then complicate this effort, with the road blocks put in place due to covid , you have an unpredictable series of timelines made even worse by international concerns and restrictions.
The Q4 report will possibly show much revenue that was unexpected. This last contract was an initial million $ and if it shows up in this Q revenue, that alone will blow the socks off YOY expectation.
So true, but so few seem to care enough to change the status quo they love so much.
It is probably over 200million and shorts are the worst of all criminals in the world, so they think nothing of helping murder cancer patients by destroying financial viability for a company with a therapy that actually works.
Bigger posting
Waiting for Dumb Media to put a negative spin on a very positive $NWBO press release. This is a victory for #GBM patients. Time for the #GBM advocacy groups to join the fight! Let's go.
— Michael Bigger (@biggercapital) December 21, 2021
I’m just frustrated with the short term traders and lack of long term investors willing to enter with determination and positive volume. Once again, 30 years ago, a biotech with the achievements to date of DCVax-L , the stock would be well into $6 +
With that time to plan, they didn’t plan.
Penny traders can’t stand to see even the smallest gain reside in their account without selling.
In a rational market, NWBO stock would already have been trading at $6+ over the last 6 months. The data to date justifies a higher price than $6 and given all information available , a partnership or more should have already been announced.
Fuddsters throughout blogs and out in force.
Thanks for the info and good work
I expect UK to be first DCVax-L approval since dcvax was the first to get Special Approval and patients were undoubtedly very closely monitored . This would have given them a definite inside knowledge as to efficacy and how it compared to SOC.
posted by @HumneyMuney.
A $NWBO patent granted on November 19, 2021 by Japan: JP2018513634 - 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法https://t.co/0BJjgykEKd@biggercapital @ATLnsider pic.twitter.com/o4tczsWIzr
— Henry (@HenryMuney) December 17, 2021
Shorting isn’t an investing style, it is a personality defect.
Umibe5690 made the well reasoned intelligent point.
Many don’t understand that fact and fail of to acknowledge all the baseless attacks launched against DCVax/NWBO .
Apparently traders have no understand how multi million $ contracts positively affect a company. The lack of buyers investigating growing companies doesn’t help either. Once again, lack of business understanding , education and desire for investment in a company growing at 300% rate, impairs those who should be investing in this company.
KULR great analytic video explaining success of company .
Fact is, any price below whatever it can get to, is a great buy price. This 3 or 4 place decimal pricing is ridiculous for this stock given the value of a new SOC
Many here can barely spell DCVax. I would think very few have any understanding of running a biotech and fewer who understand running a successful international clinical.
For those who have experience based knowledge, I appreciate your every post.
FDA, Bought and paid by their owners, big pharma.